Data Access NOTE: Please refer to the “Authorized Access” section below for information about how access to the data from this accession differs from many other dbGaP accessions. Objectives The Beta-Blocker Evaluation of Survival Trial was designed to determine whether bucindolol hydrochloride- a nonselective beta-adrenergic blocker and mild vasodilator- would reduce the rate of death from any cause among patients with advanced heart failure and to assess its effects in various subgroups defined by ethnic background and demographic criteria- specifically women and members of minority groups. Background Although beta-adrenergic-receptor antagonists reduce morbidity and Mortality in participants with mild-to-moderate chronic heart failure, their effort on survival in participants with more advanced heart failure is unknown. Participants There were 2,708 participants. Conclusions Bucindolol resulted in no significant overall survival benefit. (Krause-Steinrauf et al., 2001, PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/11386264/">11386264</a>).

Beta-Blocker Evaluation in Survival Trial (BEST-BioLINCC)

Cardiovascular Diseases study on BDC (2,707 participants)

Beta-Blocker Evaluation in Survival Trial (BEST-BioLINCC)

Description

Applying For Access

Summary